Orum Therapeutics

At a glance

Orum Therapeutics filed 61 disclosures in the last 12 months, including 10 5% holder, 5 insider and 2 issuance. The most recent key filing was on Oct 29: CEO bought 10,000 sh on the market at an average ₩17,176, Oct 23.

Revenue for 2025 was ₩23.6M, down 99.9% on 2024. It made an operating loss of ₩51.8B. Debt was 29% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩24.1M and operating loss of ₩33.4B.

The 2025 annual report lists 21 employees with an average tenure of 3.7 years and average pay of ₩174.2M. Its 5 directors and auditors were paid ₩322M each on average. It paid no cash dividend for 2025. 이승주 and related parties held 16.40% at year end.

Of 1 recent 5%+ holder report, 0 raised and 1 cut a stake; the largest stake reported was 15.79% on Oct 21.

From the 2025 annual report

Staff: 21 (6 men, 15 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩3.7B. Directors and auditors: 5, paid ₩1.6B in total.

No cash dividend was paid for 2025.

Largest shareholder

이승주 holds 15.96%; with 3 related parties the group holds 16.40% of common shares at year end (from 16.65% at the start of the year).

Auditor: 성현회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports